ASNC 2024 Nuclear cardiology Board Exam Prep Course
Overview
Whether you are preparing for the 2024 CBNC Nuclear Cardiology Board Exams or want to stay current on board-focused updates in nuclear cardiology, the ASNC Nuclear Cardiology Board Exam Prep Course is right for you. Esteemed Board Prep faculty teach to the CBNC objectives in their 19 pre-recorded presentations and will walk through the answer explanations to the more than 160 practice questions and much more.
Target Audience
This course is designed for cardiologists, nuclear medicine physicians, and radiologists preparing for the certification or recertification exam in nuclear cardiology.
Learner Objectives
The primary objectives of the course are to enable participants to achieve the following:
- Apply nuclear cardiovascular imaging physics and instrumentation
- Explain image acquisition and processing considerations and identify associated artifacts
- Discuss the production and management of radionuclides and radiopharmaceuticals
- Incorporate patient-centered imaging principles and appropriate use considerations in nuclear cardiology and stress procedure selection
- Incorporate risk stratification into selection and application of nuclear cardiology studies
- Integrate radiation safety standards into professional nuclear cardiology practice
- Apply nuclear imaging tools in assessment of myocardial viability and cardiac amyloidosis
- Understand the basics of positron emission tomography (PET) imaging for myocardial perfusion and metabolic viability and sarcoidosis assessment
- Interpret SPECT and PET perfusion and metabolic images and ventricular function imaging
- Utilize myocardial perfusion imaging in the assessment, diagnosis, and response to therapy in patients with known or suspected coronary artery disease and special populations
- Appropriately identify non-cardiac findings on SPECT and PET-CT cardiovascular imaging studies
- Integrate nuclear cardiology into the multimodality imaging evaluation of cardiovascular disease
Overall Goal
The overall goal of this activity is to increase physician competence in nuclear cardiology by providing a comprehensive review, including the most up-to-date information, developments, treatment protocols, methodology, and best test for the right patient at the right time to optimize patient outcomes in their nuclear cardiology practice.
Statement of Need
Radionuclide-based cardiac imaging studies, including myocardial perfusion imaging (MPI), play an important role in the diagnosis and management of patients with suspected or known heart disease. Today more than 5000 laboratories are performing an estimated 8 million myocardial perfusion studies, of which 58% use pharmacological stress agents, either alone or with exercise.* A large body of scientific evidence exists on the clinical value of MPI, based on studies performed on many thousands of patients. These studies are highly sensitive and specific for the diagnosis, prognosis, and treatment response of coronary artery disease, as well as for selection of patients who may benefit from other types of intervention, including revascularization and device therapy. The value and justification of MPI for risk assessment is based on large observational outcome studies. As a result of the recognized clinical value and cost effectiveness of these studies, they have been incorporated into many ACC/American Heart Association (AHA)/ASNC clinical management guidelines.
Nuclear cardiology is an evolving field with continuing advances in software, instrumentation, and radiopharmaceuticals to provide high quality, clinically relevant information for patient care. These advances require those involved in providing nuclear cardiology studies to be updated continuously, to ensure the procedures are used appropriately and safely, and to assure recent clinical and technological advances are incorporated in a timely manner to continually improve the image quality and interpretation to provide the best clinical care.
*Dicardiology.com. IMV market report. Posted December 26, 2013.
Price : $ 100
